Cynthia M Simbulan-Rosenthal
Overview
Explore the profile of Cynthia M Simbulan-Rosenthal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alobaidi R, Islam N, Olkey T, Haribabu Y, Shamo M, Sykora P, et al.
Cells
. 2025 Feb;
14(4).
PMID: 39996721
Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MICs), implicated in tumorigenesis, invasion, and drug resistance, and characterized by an elevated expression of stem cell markers, including CD133....
2.
Carney B, Simbulan-Rosenthal C, Rosenthal D, Shupp J
Front Biosci (Landmark Ed)
. 2024 Jun;
29(6):230.
PMID: 38940034
Background: Existing animal models for testing therapeutics in the skin are limited. Mouse and rat models lack similarity to human skin in structure and wound healing mechanism. Pigs are regarded...
3.
Simbulan-Rosenthal C, Islam N, Haribabu Y, Alobaidi R, Shalamzari A, Graham G, et al.
Cells
. 2024 May;
13(9.
PMID: 38727313
CD133, a cancer stem cell (CSC) marker in tumors, including melanoma, is associated with tumor recurrence, chemoresistance, and metastasis. Patient-derived melanoma cell lines were transduced with a Tet-on vector expressing...
4.
Rosenthal D, Kuo L, Seagrave S, Soni V, Islam N, Minsky G, et al.
Genes (Basel)
. 2023 Mar;
14(3.
PMID: 36980902
The targets of topical genotoxic agents are basal and stem cells of the skin. These cells may misrepair DNA lesions, resulting in deleterious mutations of tumor suppressors or oncogenes. However,...
5.
Simbulan-Rosenthal C, Haribabu Y, Vakili S, Kuo L, Clark H, Dougherty R, et al.
Int J Mol Sci
. 2022 Feb;
23(4).
PMID: 35216449
Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MIC) implicated in tumorigenesis, invasion, and drug resistance, and is characterized by the elevated expression of stem cell markers, including...
6.
Issa N, Wathieu H, Glasgow E, Peran I, Parasido E, Li T, et al.
Ecotoxicol Environ Saf
. 2022 Feb;
233:113330.
PMID: 35189517
Environmental chemical (EC) exposures and our interactions with them has significantly increased in the recent decades. Toxicity associated biological characterization of these chemicals is challenging and inefficient, even with available...
7.
Carney B, Travis T, Moffatt L, Johnson L, McLawhorn M, Simbulan-Rosenthal C, et al.
PLoS One
. 2021 Mar;
16(3):e0248985.
PMID: 33765043
There are limited treatments for dyschromia in burn hypertrophic scars (HTSs). Initial work in Duroc pig models showed that regions of scar that are light or dark have equal numbers...
8.
Carney B, Simbulan-Rosenthal C, Gaur A, Browne B, Moghe M, Crooke E, et al.
Regen Ther
. 2021 Jan;
15:138-148.
PMID: 33426212
Wound healing requires well-coordinated events including hemostasis, inflammation, proliferation, and remodeling. Delays in any of these stages leads to chronic wounds, infections, and hypertrophic scarring. Burn wounds are particularly problematic,...
9.
Simbulan-Rosenthal C, Dougherty R, Vakili S, Ferraro A, Kuo L, Alobaidi R, et al.
Cancers (Basel)
. 2019 Oct;
11(10).
PMID: 31623313
CD133, known as prominin1, is a penta-span transmembrane glycoprotein presumably a cancer stem cell marker for carcinomas, glioblastomas, and melanomas. We showed that CD133(+) 'melanoma-initiating cells' are associated with chemoresistance,...
10.
Carney B, Dougherty R, Moffatt L, Simbulan-Rosenthal C, Shupp J, Rosenthal D
J Burn Care Res
. 2019 Sep;
41(2):339-346.
PMID: 31541238
Burn injuries frequently result in hypertrophic scars (HTSs), specifically when excision and grafting are delayed due to limited resources or patient complications. In patient populations with dark baseline pigmentation, one...